Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is a biopharmaceutical company whose core business of developing and marketing novel therapeutics inherently requires animal testing for regulatory compliance and product development. The company's lead commercial product, Pyrukynd (mitapivat), and its pipeline of investigational drugs are subject to mandatory non-clinical safety assessments by global health authorities like the U.S. Food and Drug Administration and the European Medicines Agency. These regulatory submissions, including the EMA-approved Risk Management Plan for Pyrukynd, document the standard preclinical toxicology and pharmacology studies conducted in animal models. As a research-based pharmaceutical firm, Agios does not publicly disclose commitments to alternative testing methods or a policy against animal testing in its 2022 ESG report, indicating reliance on conventional animal-based research to advance its clinical programs for genetically defined diseases.